4 Healthcare Stock Stories Buzzing Along On Monday

Vivus (NASDAQ:VVUS): Closing price $12.41

On Monday, Vivus reported that the initial availability of Qsymia (phentermine and topiramate extended-release) capsules CIV in thousands of certified retail pharmacies will be earlier than the previously stated mid-July schedule. The prescription-only medication Qsymia is initially available as of Monday in around 8,000 Walgreens, Costco, and Duane Reade retail pharmacies across the United States. Vivus will continue to certify and augment the Qsymia retail pharmacy network with well-known national and regional chains, and with independent pharmacies, in the coming weeks and months.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Achillion Pharmaceuticals (NASDAQ:ACHN): Closing price $8.36

Achillion said that it has been advised by the FDA that a clinical hold has been put on sovaprevir, following elevations in liver enzymes linked with significantly higher than expected exposures to atazanivir and sovaprevir. The announcement was made following a Phase 1 healthy subject drug-drug interaction study evaluating the effects of concomitant administration of sovaprevir with ritonavir-boosted atazanavir. The FDA has permitted continued enrollment and treatment of patients in the Phase 2 -007 clinical trial that examines 12-weeks of sovaprevir in combination with ACH-3102 and ribavirin for patients with treatment-naive genotype 1 hepatitis C viral infection.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACHN

 Covidien (NYSE: COV): Closing price $57.46

The worldwide supplier of healthcare products announced Monday that it has finalized the separation of its pharmaceuticals arm, which is now held by Mallinckrodt, a new independent firm. Mallinckrodt commenced regular way trading on the New York Stock Exchange Monday under the symbol “MNK.” The distribution of Mallinckrodt ordinary shares occurred on Friday. In the distribution, Mallinckrodt issued one ordinary share per every eight Covidien ordinary shares held as of the close on June 19th, the record date for the distribution.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

COV

BioMarin Pharmaceutical (NASDAQ:BMRN): Closing price $59.44

BioMarin said that it has submitted the Vimizim Marketing Application to the Agência Nacional de Vigilancia Sanitaria, or the National Health Surveillance Agency of Brazil. Assuming the award of priority review status, based on orphan drug status in the United States and the European Union, an approval decision from ANVISA is expected in mid-2014.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BMRN

Don’t Miss: Are Pfizer and These Companies at Risk in Venezuela?